13F Holdings
中文EN

MTVA MetaVia Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1638287 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY3.2%
TTM EPS YoY93.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-359.0%
ROA-129.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets74.8%
Debt / equity0.00x
Current ratio1.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.06x
Accruals ratio7.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$6.80M$21.55M$9.16M$2.78M$6.55M
SG&A expense$6.91M$7.26M$6.73M$8.64M$8.75M
Operating income-$13.71M-$28.81M-$15.89M-$19.63M-$15.30M
Pretax income-$12.97M-$27.59M-$12.47M-$13.97M-$15.28M
Income tax$0$0$0$0$0
Net income-$12.97M-$27.59M-$12.47M-$13.97M-$15.28M
EBITDA-$13.69M-$28.79M-$15.88M-$19.61M-$15.25M
EPS (basic)-7.35-39.13-2.46-43.42-19.81
EPS (diluted)-7.35-39.13-2.46-43.42-19.81
Weighted avg. shares (diluted)1.77M705,1935.07M321,703771,422
Banking
Net interest income$510,000$920,000$461,000—$14,000
Balance sheet
Cash & equivalents$10.28M$16.02M$22.43M$33.36M$16.39M
Current assets$10.88M$16.07M$22.51M$33.53M$16.58M
PP&E, net$17,000$34,000$46,000$2,000$110,000
Total assets$11.12M$16.26M$22.78M$33.53M$16.80M
Current liabilities$5.65M$8.27M$5.96M$11.78M$2.16M
Total liabilities$5.79M$8.33M$6.10M$11.78M$2.20M
Shareholders' equity$5.33M$7.93M$16.68M$21.75M$14.60M
Shares outstanding2.31M785,1944.91M3.18M888,693
Cash flow statement
Operating cash flow-$15.70M-$24.71M-$10.80M-$11.71M-$15.13M
Capital expenditure$2,000$8,000$50,000—$3,000
Free cash flow-$15.70M-$24.72M-$10.85M—-$15.14M
Investing cash flow-$2,000-$8,000-$50,000$8,000-$586,000
Financing cash flow$9.96M$18.30M-$80,000$28.68M$22.03M
Depreciation & amortization$19,000$20,000$6,000$20,000$48,000
Stock-based compensation$411,000$538,000$222,000$854,000$662,000

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.